tcsc2747 Flumequine

Flumequine is a quinolone antibiotic, and acts as a topoisomerase II inhibitor, with an IC₅₀ of 15 μM (3.92 μg/mL).

IC50 & Target: IC50: 15 μM (Topoisomerase II)^[1]

In Vitro: Flumequine is a topoisomerase II inhibitor, with an IC₅₀ of 3.92 μg/mL, and less potently inhibits Gyrase, with an IC₅₀ of 1764 μg/mL. Flumequine (0-625 μg/mL) increases migration of nuclear DNA from CHL cells^[1]. Flumequine inhibits Spanish field isolates of B. hyodysenteriae with MIC₅₀ and MIC₉₀ of 50 and 100 μg/mL, and MBC₅₀ and MBC₉₀ of 50, 200 μg/mL, respectively^[2]. Flumequine suppresses A. salmonicida isolates with MIC ranging from 0.06 to 32 μg/mL^[3].

In Vivo: Flumequine (0-500 mg/kg, p.o.) causes dose-related DNA damage in the stomach, colon, and urinary bladder of mice, 1 and 3 h but not 24 h after its administration^[1].